---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000070"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:15:29.795416+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Caribou Q1 net loss $28M, cash $291M; CB-010 dose expansion enrolling, CB-011 dosing initiated

## Summary
- Net loss of $28.0M in Q1 2023, vs $19.1M in Q1 2022, driven by higher R&D expenses.
- Cash and equivalents $291.0M as of March 31, 2023; cash runway into 2025.
- R&D expenses rose to $25.7M (Q1 2023) from $13.9M (Q1 2022) to advance pipeline.
- CB-010 ANTLER trial enrolling second-line LBCL in dose expansion; plan to report data H2 2023.
- CB-011 CaMMouflage Phase 1 dosing at dose level 1 for r/r multiple myeloma; IND for CB-012 planned H2 2023.

## SEC filing metadata
- accession: 0001619856-23-000070
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/0001619856-23-000070-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/crbu-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000070
- JSON: https://secwatch.observer/filing/0001619856-23-000070.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000070.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported three months ended March 31, 2023 results: revenue $3.5 million, net income $28.0 million net loss.
  - Period: three months ended March 31, 2023
  - Revenue: $3.5 million
  - Net income: $28.0 million net loss
  - Result: reported results
  source text: First Quarter 2023 Financial Results Cash, cash equivalents, and marketable securities: Caribou had $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023, compared to $317.0 million as of December 31, 2022. Caribou expects its cash, cash equivalents, and marketable securities will be sufficient to fund its current operating plan into 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $3.5 million for the three months ended March 31, 2023, compared to $2.7 million for the same period 2022. The increase was primarily due to revenue recognized under the Collaboration and License Agreement with AbbVie and other license agreements. R&D expenses: Research and development expenses were $25.7 million for the three months ended March 31, 2023, compared to $13.9 million for the same period in 2022. The increase was primarily due to costs to advance pipeline programs, including the ANTLER and CaMMouflage
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000070/0001619856-23-000070-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.